What's breaking now, across thousands of outlets.
New data on a closely watched Lyme disease vaccine from Pfizer and Valneva provide details on the near-miss in one of two analyses, as the vaccine's commercial future hangs in the balance. Unveiled Thursday at ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Vorzeitig bekannt gewordene Studiendaten zu einem Krebsimpfstoff setzen Moderna und Merck & Co. unter Druck. Zeitweise verlor die Moderna-Aktie bis zu 26 Prozent.
Prematurely disclosed study data on a cancer vaccine are putting pressure on Moderna and Merck & Co. Moderna's stock temporarily loses 26 percent.
Public confidence in the CDC and FDA has fallen to record lows, with just 26% and 25% of Americans, respectively, rating the agencies’ performance as excellent or good in a Gallup poll.
Moderna shares plunged as much as 25% after partial clinical trial data leaked for its personalized cancer vaccine developed with Merck, despite the full results showing promising outcomes for melanoma patients. Analysts attribute the selloff largely to inflated investor expectations rather than disappointing clinical results.
The WHO said it was working with French authorities to establish the source of the infection, possible routes of transmission and any potential public health risks The post France reports first human case of Shamonda virus as patient dies appeared first on Premium Times Nigeria .
(MedPage Today) -- Neurokinin (NK)-receptor antagonists improved sleep disturbances in menopausal women, a meta-analysis of randomized controlled trials showed. Among women with moderate-to-severe vasomotor symptoms, the agents were associated...
